Hims & Hers Health (NYSE:HIMS) Trading Up 4.7%

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price shot up 4.7% during trading on Monday . The company traded as high as $18.65 and last traded at $18.61. 3,078,922 shares were traded during mid-day trading, a decline of 60% from the average session volume of 7,669,326 shares. The stock had previously closed at $17.77.

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Piper Sandler restated a “neutral” rating and set a $18.00 price target on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Bank of America dropped their target price on Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, September 13th. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Finally, Jefferies Financial Group boosted their target price on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, June 27th. Eight equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.86.

Hims & Hers Health Trading Up 3.7 %

The stock has a market cap of $3.96 billion, a price-to-earnings ratio of -1,777.00 and a beta of 1.05. The firm’s 50-day moving average is $16.93 and its two-hundred day moving average is $17.19.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The firm had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. During the same period in the prior year, the business posted ($0.03) EPS. The business’s revenue for the quarter was up 51.8% compared to the same quarter last year. On average, analysts predict that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In related news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $20.75, for a total value of $3,919,426.00. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $695,166.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, Director Christiane Pendarvis sold 7,000 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total value of $106,050.00. Following the completion of the transaction, the director now directly owns 23,917 shares of the company’s stock, valued at $362,342.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $20.75, for a total transaction of $3,919,426.00. Following the sale, the chief executive officer now owns 33,502 shares in the company, valued at approximately $695,166.50. The disclosure for this sale can be found here. In the last three months, insiders sold 731,473 shares of company stock valued at $12,671,277. Insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently modified their holdings of HIMS. Vanguard Group Inc. boosted its holdings in Hims & Hers Health by 1.0% in the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock valued at $221,379,000 after acquiring an additional 136,907 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after acquiring an additional 3,205,108 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Hims & Hers Health by 9.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock valued at $19,117,000 after acquiring an additional 193,507 shares in the last quarter. Farallon Capital Management LLC boosted its position in Hims & Hers Health by 3,890.5% during the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after purchasing an additional 1,634,000 shares during the period. Finally, Verition Fund Management LLC increased its holdings in Hims & Hers Health by 30.9% in the 4th quarter. Verition Fund Management LLC now owns 798,660 shares of the company’s stock valued at $7,108,000 after purchasing an additional 188,506 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.